1.Research on the chemical induction scheme for functional insulin producing cell
Yiwen LI ; Jibing CHEN ; Weiping LIANG ; Hongjun GAO ; Zhiran XU
Organ Transplantation 2025;16(3):435-442
Objective To explore the effective induction scheme for differentiation of adipose-derived mesenchymal stem cell (ADMSC) to insulin producing cell (IPC). Methods Different schemes of small molecule compound were used to induce the differentiation of ADMSC. The purity of cells was analyzed by flow cytometry and the morphological changes of cells were observed under the microscope. The quality, performance and insulin related indicators of cells were detected by hematoxylin-eosin and immunohistochemical staining. The maturity and activity of cells were detected by dithizone (DTZ) and diacetylfluorescein/propidium iodide staining. The induction effect of ADMSC differentiated into IPC was analyzed. Results The purity of ADMSC reached more than 99%, and the sphere forming properties of schemes Ⅰ, Ⅱ and Ⅲ were good. Cell induction mass, the expression effects of pancreatic and duodenal homeobox 1 (PDX1), musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) and insulin and C peptide of schemes Ⅰ were both better than those of other schemes. The DTZ staining depth may be related to IPC maturity, among which the number of apoptotic cells in scheme Ⅰ was significantly less than that of scheme Ⅱ and Ⅲ. Conclusions Induction scheme Ⅰ may improve the differentiation efficiency of ADMSC to IPC and lay a certain foundation for future clinical IPC transplantation applications.
2.Endoscopic transorbital approach to the orbital apex and skull base: an applied anatomical study
Jimin LIU ; Yihui WEN ; Yinyan LAI ; Zhaofeng XU ; Wenxiang GAO ; Nianzhen ZHENG ; Jian LI ; Weiping WEN
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2025;60(9):1054-1061
Objective:To investigate the anatomical feasibility of the endoscopic transorbital approach (ETOA) to the orbital apex and lateral middle cranial fossa, to identify stable and recognizable surgical landmarks under endoscopic visualization, and to provide morphometric data for preoperative planning and intraoperative navigation.Methods:Stepwise anatomical dissection was performed on five formalin-fixed cadaveric heads and one fresh arterially injected cadaveric specimen to simulate the ETOA using a 0° endoscope. Key structures and their anatomical relationships were observed and recorded. Additionally, high-resolution CT scans of 50 adults were retrospectively analyzed. Three-dimensional reconstructions and measurements were performed using Mimics 17.0 software. Spatial validation was performed using 17 dry skulls to verify the consistency and reliability of osseous anatomical landmarks.Results:Cadaveric dissection identified the meningo-orbital band, superior orbital fissure, optic canal, foramen rotundum, and foramen ovale as reliable surgical landmarks for the ETOA. A topographic map of the surgical region was established based on the endoscopic view. CT measurements revealed the following distances (Mean±SD): the midpoint of the supraorbital rim to the foramen rotundum (57.31±3.59) mm and foramen ovale (71.46±3.42) mm; the lateral orbital rim to the lateral edge of the superior orbital fissure (37.38±2.52) mm; the distance from the superior orbital fissure to the optic canal (9.98±1.49) mm; and the distance from the anterior ethmoidal artery to the optic canal (19.98±2.05) mm. These measurements were consistent with dry skull data, indicating that these osseous landmarks had stable spatial relationships and were suitable for intraoperative localization.Conclusions:The ETOA provides favorable anatomical accessibility and clinical feasibility for lesions involving the orbital apex and lateral skull base. Key osseous structures demonstrate high identifiability and stable spatial relationships, serving as critical references for intraoperative navigation and preoperative pathway planning. The quantitative anatomical framework established in this study provides critical morphometric support for minimally invasive surgery targeting lesions in this region.
3.Efficacy of remimazolam-based anesthesia in daytime laparoscopic cholecystectomy: a multicenter, non-inferiority, randomized controlled trial
Qian HU ; Jian GUO ; Haijun YUAN ; Weiping LEI ; Haipeng LIU ; Chen YONG ; Yanhui HU ; Junping CHEN ; Jianliang SUN ; Zhijian LAN ; Jianhong XU ; Xin YU ; Gang CHEN
Chinese Journal of Anesthesiology 2025;45(6):720-725
Objective:To evaluate the efficacy of remimazolam-based anesthesia in daytime laparoscopic cholecystectomy.Methods:In this multicenter, non-inferiority, randomized controlled trial, 300 American Society of Anesthesiologists Physical Status classification Ⅰ or Ⅱ patients of either sex, aged 18-60 yr, with body mass index of 18-28 kg/m 2, who underwent daytime laparoscopic cholecystectomy under general anesthesia with tracheal intubation at Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou First People′s Hospital Affiliated to Westlake University School of Medicine, Ningbo No. 2 Hospital, and the Second Affiliated Hospital of Nanchang University from August 2021 to August 2023, were selected and divided into 2 groups ( n=150 each) using a random number table method: remimazolam group (R group) and propofol group (P group). Anesthesia was induced as follows: Sufentanil was intravenously injected at a rate of 0.5 μg/kg, remimazolam was intravenously injected at a rate of 0.3 mg/kg in group R, propofol was intravenously injected at a rate of 2.0-2.5 mg/kg in group P, and cisatracurium besilate was intravenously injected at a rate of 0.2 mg/kg after loss of consciousness in two groups. The patients were mechanically ventilated after tracheal intubation. Anesthesia was maintained as follows: Remimazolam was intravenously injected at a rate of 0.5-1.0 mg·kg -1·h -1 in group R, propofol was intravenously injected at a rate of 4-10 mg·kg -1·h -1 in group P, and remifentanil was intravenously infused at a rate of 0.25-2.00 μg·kg -1·min -1, maintaining intraoperative bispectral index value of 40-60. The success rate of sedation was recorded, and non-inferiority tests were conducted. The time to loss of consciousness, emergence time, extubation time, recovery time of orientation, time of stay in post-anesthesia care unit and occurrence of delayed emergence were recorded. Liver function and renal function were measured before operation and within 24 h after operation. The occurrence of abnormal alanine transaminase, abnormal aspartate transaminase, abnormal creatinine and abnormal urea was recorded. The occurrence of adverse reactions during and after operation was recorded. Results:The success rates of sedation were 98.6% and 99.3% in group R and group P, respectively, there was no statistically significant difference in the success rate of sedation between the two groups ( P>0.05), and the difference in the success rates of sedation between the two groups was -0.007 (95% confidence interval-0.0301-0.0161), which met the pre-set non-inferiority criteria(95% confidence interval >-0.055). Compared with group P, the time to loss of consciousness and recovery time of orientation were significantly prolonged, and the incidence of delayed emergence was increased ( P<0.05), and no statistically significant changes were found in the emergence time, extubation time, time of stay in post-anesthesia care unit and severity of postoperative nausea and vomiting in group R ( P>0.05). There was no statistically significant difference in the abnormal rates of alanine transaminase, aspartate transaminase, creatinine and urea before and after operation between the two groups ( P>0.05). Conclusions:The efficacy of remimazolam-based anesthesia in daytime laparoscopic cholecystectomy is not inferior to that of propofol-based anesthesia.
4.Association between edentulism and the risk of social isolation in middle-aged and older adults
DUAN Chengwei ; LUO Mingyi ; FAN Chenrui ; XU Jialei ; MUHETAER Tureke ; XU Mengyuan ; WAN Weiping ; LIAO Haiqing ; WU Zeni
Journal of Prevention and Treatment for Stomatological Diseases 2025;33(12):1070-1077
Objective:
To investigate the association between edentulism and the risk of social isolation in middle-aged and elderly populations, provide empirical evidence for formulating social isolation prevention and intervention policies targeting edentulous middle-aged and elderly populations.
Methods:
Data were derived from the baseline survey (2011) and three follow-ups (2013, 2015, 2018) of the China Health and Retirement Longitudinal Study (CHARLS). Participants were enrolled in the follow-up from the baseline. Those identified as socially isolated in any of the follow-up surveys conducted in 2013, 2015, or 2018 were considered to have reached the endpoint; otherwise, the follow-up was continued until the end of the 2018 survey; 9 870 individuals were ultimately included. Subjects were grouped by edentulism status. Chi-square test and multivariate Cox regression analysis were performed using Stata 17.0.
Results:
During a median follow-up of 6.54 years, 1 800 cases of social isolation occurred, with an incidence rate of 18.23%(17.47%~18.99%). Multivariate Cox regression showed that edentulism was associated with an increased risk of social isolation (HR=1.21, 95% CI: 1.03-1.42) after adjusting for confounders. Subgroup analysis revealed population heterogeneity. Sensitivity analyses confirmed the stability of the results.
Conclusion
Edentulism is associated with an increased risk of social isolation in middle-aged and elderly adults.
5.Diagnostic value of endoscopic ultrasonography for common bile duct microlithiasis
Gang Chen ; Weiping Zhang ; Junjun Bao ; Yang Li ; Qiao Mei ; Jianming Xu ; Rutao Hong
Acta Universitatis Medicinalis Anhui 2025;60(1):147-151
Objective :
To investigate the diagnostic value of linear array endoscopic ultrasonography ( EUS) for common bile duct microlithiasis.
Methods :
Data of patients who attended in the hospital and diagnosed as common bile duct microlithiasis and biliary sludge by EUS were selected.A total of 85 patients with magnetic resonance cholangiopancreatography ( MRCP) examination and ERCP treatment during hospitalization were enrolled.The results of endoscopic retrograde cholangiopancreatography / endoscopic sphincterotomy ( ERCP / EST) were the gold standard for diagnosis.The results of EUS,MRCP,and diagnostic ERCP were compared with the gold standard, and the sensitivity,specificity,positive predictive value,negative predictive value,and diagnostic accuracy of the three methods were calculated,respectively.The chi-square test was used for comparison of the above indices.
Results :
Of all 85 patients,63 had positive EUS results,among whom 5 had false positive results; 22 had negative EUS results,among whom 1 had false negative results.Of all 85 patients,49 had positive MRCP results,among whom 4 had false positive results; 36 had negative MRCP results,among whom 14 had false negative results.Of all 85 patients,59 had positive diagnostic ERCP results,among whom 10 had false positive results; 26 had negative diagnostic ERCP results,among whom 10 had false negative results.The sensitivity,specificity,positive predictive value( PPV) ,negative predictive value ( NPV) ,and accuracy of EUS in diagnosing common bile duct microlithia- sis were 98. 3% ,80. 8% ,92. 1% ,95. 4% and 92. 9% ,respectively. For MRCP,these values were 76. 3% , 84. 6% ,91. 8% ,61. 1% and 78. 8% ,respectively.For diagnostic ERCP,these values were 83. 1% ,61. 5% , 83. 1% ,61. 5% and 76. 5% ,respectively.The EUS group had a significantly higher accuracy than the MRCP group ( χ2 = 6. 986,P <0. 05) and diagnostic ERCP group ( χ2 = 8. 900,P <0. 05) .The areas under the ROC curves ( AUC) and 95% CI of EUS group,MRCP group and diagnostic ERCP were 0. 895 ( 95% CI: 0. 802 - 0. 988,P<0. 001) ,0. 804 ( 95% CI: 0. 702 -0. 907,P <0. 001) and 0. 723 ( 95% CI: 0. 598 -0. 848,P = 0. 001) ,respectively.
Conclusion
EUS has a high diagnostic value in the diagnosis of common bile duct microli- thiasis and thus can be used as the preferred examination before therapeutic ERCP.
6.Mechanism of microRNA-214-3p targeting CHUK in chemosensitivity of ibrutinib by regulating nuclear factor-κB pathway
Yiqi FANG ; Qianwen BAI ; Xiaodu XU ; Bing WU ; Weiping WU ; Jing QIAN
Journal of Clinical Medicine in Practice 2025;29(11):72-78,84
Objective To investigate the mechanism of microRNA-214-3p(miR-214-3p)targe-ting CHUK to regulate the nuclear factor(NF)-κB pathway in modulating the chemosensitivity of lym-phoma cells to ibrutinib.Methods The half-maximal inhibitory concentration(IC50)was used to verify the ibrutinib-resistant cell model.The expression levels of miR-214-3p and CHUK mRNA in tissues and cells were detected by quantitative real-time polymerase chain reaction(qRT-PCR).Western blotting(WB)was employed to assess CHUK protein levels.A dual-luciferase reporter assay was performed to confirm the direct targeting relationship between miR-214-3p and CHUK.Cell viability was measured using CCK-8 assay.Flow cytometry was used to evaluate cell apoptosis.The expression of the NF-κB p65 signaling pathway was detected by WB.Results The CHUK mRNA and CHUK protein expression levels were higher in ibrutinib-resistant cells than in control cells(P<0.05).The qRT-PCR results showed that miR-214-3p was downregulated in ibrutinib-resistant cells.The dual-luciferase reporter assay confirmed that miR-214-3p directly targeted CHUK.Transfection of miR-214-3p mimics and knockdown of CHUK(si-CHUK)reduced the number of colony-forming cells,whereas transfection of miR-214-3p inhibitor increased the number of colony-forming cells(P<0.05).Transfection of miR-214-3p mimics and knockdown of CHUK(si-CHUK)can promote apoptosis,while transfection of miR-214-3p inhibitor can inhibit apoptosis(P<0.05).Inhibition of the NF-κB p65 pathway was observed in cells transfected with miR-214-3p mimics(P<0.05).Conclusion MiR-214-3p may regulate the NF-κB p65 pathway by targeting the expression of CHUK,thereby enhancing the chemosensitivity of ibrutinib to lymphoma.
7.Inclisiran in the treatment of dyslipidemia:a rapid health technology assessment
Lingbin CHEN ; Weiping PAN ; Zhou CHEN ; Wentan XU
Chinese Journal of Pharmacoepidemiology 2025;34(10):1198-1205
Objective To evaluate the efficacy,safety and economy of inclisiran in the treatment of dyslipidemia by rapid health technology assessment,and to provide evidence-based basis for clinical treatment.Methods PubMed,Web of Science,Embase,Cochrane Library,CNKI,WanFang Data,VIP,SinoMed databases,and official websites of health technology assessment(HTA)institutions were systematically searched to collect HTA reports,systematic reviews/Meta-analysis and pharmacoeconomic studies on inclisiran for the treatment of dyslipidemia from inception to December 31,2024.Two researchers independently screened the literature,extracted information and performed quality assessment of the included literature,and then qualitative synthesis and analysis of the findings were conducted.Results A total of 8 studies were included,comprising 7 systematic reviews/Meta-analysis and 1 pharmacoeconomic study.In terms of efficacy,inclisiran significantly reduced low-density lipoprotein cholesterol,apolipoprotein B,total cholesterol,triglycerides and non-high-density lipoprotein cholesterol levels in patients with dyslipidemia compared to placebo.In terms of safety,the incidence of adverse drug reactions associated with inclisiran did not differ significantly from that of placebo,with the most common adverse drug reactions being mild injection site reactions.In terms of cost-effectiveness,the current price of inclisiran made its combination therapy with statins economically unfavorable compared to statin monotherapy.Conclusion The efficacy and safety of inclisiran in the treatment of dyslipidemia are good.However,due to its current pricing,the combination therapy of inclisiran with statins is not yet cost-advantageous compared to statin monotherapy in clinical practice.
8.Effects of entecavir on tear secretion and tear film function in patients with hepatitis B virus infection
Weiping HU ; Liyang NI ; Huangfang YING ; Zilong ZHANG ; Yonggen XU
Chinese Journal of Primary Medicine and Pharmacy 2025;32(10):1509-1512
Objective:To analyze the effects of entecavir on tear secretion and tear film function in patients with hepatitis B virus (HBV) infection.Methods:A retrospective analysis was conducted on the clinical data of 24 patients with HBV infection who received treatment with entecavir at the Department of Ophthalmology, Affiliated Hospital of Shaoxing University from April to October 2022. The relevant examination results of dry eye in these patients were analyzed before medication and at 1 and 3 months after medication.Results:Before medication, 13 cases (54.17%) had dry eye, and 3 months after medication, 17 cases (70.83%) had dry eye. At 1 and 3 months after treatment with entecavir, the Ocular Surface Disease Index values of the patients were (13.83 ± 7.11) points and (15.29 ± 6.94) points, respectively. There was no significant difference in Ocular Surface Disease Index value between before and after treatment ( t = -0.24, -1.24, both P>0.05). At 1 and 3 months after treatment, the Schirmer I test results were (8.74 ± 2.40) mm and (8.21 ± 2.40) mm, respectively. The Schirmer I test results at 3 months after treatment were significantly lower than those before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the tear film break-up time was reduced to (7.63 ± 1.97) seconds, which was significantly shorter than the value recorded before treatment ( t = 2.12, P<0.05). At 3 months after treatment, the height of the tear meniscus was (0.21 ± 0.06) mm, which was significantly different from that measured before treatment ( t = 2.26, P<0.05).At 3 months after treatment, the red eye index increased compared with the value recorded before treatment, but the difference was not statistically significant ( t = -0.35, -0.94, both P>0.05). Conclusions:Patients with HBV infection are prone to developing dry eye syndrome. After treatment with entecavir, there may be a reduction in tear secretion and a decline in tear film function, which should be a concern for clinicians.
9.Efficacy of remimazolam-based anesthesia in daytime laparoscopic cholecystectomy: a multicenter, non-inferiority, randomized controlled trial
Qian HU ; Jian GUO ; Haijun YUAN ; Weiping LEI ; Haipeng LIU ; Chen YONG ; Yanhui HU ; Junping CHEN ; Jianliang SUN ; Zhijian LAN ; Jianhong XU ; Xin YU ; Gang CHEN
Chinese Journal of Anesthesiology 2025;45(6):720-725
Objective:To evaluate the efficacy of remimazolam-based anesthesia in daytime laparoscopic cholecystectomy.Methods:In this multicenter, non-inferiority, randomized controlled trial, 300 American Society of Anesthesiologists Physical Status classification Ⅰ or Ⅱ patients of either sex, aged 18-60 yr, with body mass index of 18-28 kg/m 2, who underwent daytime laparoscopic cholecystectomy under general anesthesia with tracheal intubation at Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou First People′s Hospital Affiliated to Westlake University School of Medicine, Ningbo No. 2 Hospital, and the Second Affiliated Hospital of Nanchang University from August 2021 to August 2023, were selected and divided into 2 groups ( n=150 each) using a random number table method: remimazolam group (R group) and propofol group (P group). Anesthesia was induced as follows: Sufentanil was intravenously injected at a rate of 0.5 μg/kg, remimazolam was intravenously injected at a rate of 0.3 mg/kg in group R, propofol was intravenously injected at a rate of 2.0-2.5 mg/kg in group P, and cisatracurium besilate was intravenously injected at a rate of 0.2 mg/kg after loss of consciousness in two groups. The patients were mechanically ventilated after tracheal intubation. Anesthesia was maintained as follows: Remimazolam was intravenously injected at a rate of 0.5-1.0 mg·kg -1·h -1 in group R, propofol was intravenously injected at a rate of 4-10 mg·kg -1·h -1 in group P, and remifentanil was intravenously infused at a rate of 0.25-2.00 μg·kg -1·min -1, maintaining intraoperative bispectral index value of 40-60. The success rate of sedation was recorded, and non-inferiority tests were conducted. The time to loss of consciousness, emergence time, extubation time, recovery time of orientation, time of stay in post-anesthesia care unit and occurrence of delayed emergence were recorded. Liver function and renal function were measured before operation and within 24 h after operation. The occurrence of abnormal alanine transaminase, abnormal aspartate transaminase, abnormal creatinine and abnormal urea was recorded. The occurrence of adverse reactions during and after operation was recorded. Results:The success rates of sedation were 98.6% and 99.3% in group R and group P, respectively, there was no statistically significant difference in the success rate of sedation between the two groups ( P>0.05), and the difference in the success rates of sedation between the two groups was -0.007 (95% confidence interval-0.0301-0.0161), which met the pre-set non-inferiority criteria(95% confidence interval >-0.055). Compared with group P, the time to loss of consciousness and recovery time of orientation were significantly prolonged, and the incidence of delayed emergence was increased ( P<0.05), and no statistically significant changes were found in the emergence time, extubation time, time of stay in post-anesthesia care unit and severity of postoperative nausea and vomiting in group R ( P>0.05). There was no statistically significant difference in the abnormal rates of alanine transaminase, aspartate transaminase, creatinine and urea before and after operation between the two groups ( P>0.05). Conclusions:The efficacy of remimazolam-based anesthesia in daytime laparoscopic cholecystectomy is not inferior to that of propofol-based anesthesia.
10.Inclisiran in the treatment of dyslipidemia:a rapid health technology assessment
Lingbin CHEN ; Weiping PAN ; Zhou CHEN ; Wentan XU
Chinese Journal of Pharmacoepidemiology 2025;34(10):1198-1205
Objective To evaluate the efficacy,safety and economy of inclisiran in the treatment of dyslipidemia by rapid health technology assessment,and to provide evidence-based basis for clinical treatment.Methods PubMed,Web of Science,Embase,Cochrane Library,CNKI,WanFang Data,VIP,SinoMed databases,and official websites of health technology assessment(HTA)institutions were systematically searched to collect HTA reports,systematic reviews/Meta-analysis and pharmacoeconomic studies on inclisiran for the treatment of dyslipidemia from inception to December 31,2024.Two researchers independently screened the literature,extracted information and performed quality assessment of the included literature,and then qualitative synthesis and analysis of the findings were conducted.Results A total of 8 studies were included,comprising 7 systematic reviews/Meta-analysis and 1 pharmacoeconomic study.In terms of efficacy,inclisiran significantly reduced low-density lipoprotein cholesterol,apolipoprotein B,total cholesterol,triglycerides and non-high-density lipoprotein cholesterol levels in patients with dyslipidemia compared to placebo.In terms of safety,the incidence of adverse drug reactions associated with inclisiran did not differ significantly from that of placebo,with the most common adverse drug reactions being mild injection site reactions.In terms of cost-effectiveness,the current price of inclisiran made its combination therapy with statins economically unfavorable compared to statin monotherapy.Conclusion The efficacy and safety of inclisiran in the treatment of dyslipidemia are good.However,due to its current pricing,the combination therapy of inclisiran with statins is not yet cost-advantageous compared to statin monotherapy in clinical practice.


Result Analysis
Print
Save
E-mail